PFM Health Sciences, LP is an SEC-registered investment adviser based in San Francisco, CA that reports managing 2 hedge funds on Form ADV. It reports $1.3 billion in regulatory assets under management. Its private funds, of all types, hold $1.2 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +17.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +41.4% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $1.3 billionForm ADV Item 5.F
- Gross assets of private funds
- $1.2 billionAll private fund types, Form ADV
- Hedge funds managed
- 24 private funds in total
- Employees
- 17Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 146747
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +24.4% | +14.8% |
| Q1 2026 | -5.8% | -4.6% |
| Q4 2025 | +18.5% | +2.4% |
| Q3 2025 | +6.9% | +7.8% |
| Q2 2025 | +1.8% | +10.4% |
| Q1 2025 | +2.8% | -4.5% |
| Q4 2024 | -11.9% | +2.1% |
| Q3 2024 | +3.3% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 79 share positions ($936,374,650) reported by PFM Health Sciences, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Ascendis Pharma A/s5.57%
- Axsome Therapeutics Inc.4.37%
- United Therapeutics Corp Del4.01%
- Tenet Healthcare Corp3.47%
- Inhibrx Biosciences Inc3.42%
- Eli Lilly & Co3.10%
- Neurocrine Biosciences Inc3.10%
- Indivior Pharmaceuticals Inc2.84%
- State STR SPDR S&P 500 ETF T2.64%
- Bridgebio Pharma Inc2.57%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Ascendis Pharma A/s | $52,142,996 | 5.57% | 228,868 | -1.85% |
| Axsome Therapeutics Inc. | $40,953,388 | 4.37% | 222,102 | +1.14% |
| United Therapeutics Corp Del | $37,522,089 | 4.01% | 69,243 | +38.51% |
| Tenet Healthcare Corp | $32,531,255 | 3.47% | 127,294 | +0.57% |
| Inhibrx Biosciences Inc | $32,058,726 | 3.42% | 320,331 | +3.87% |
| Eli Lilly & Co | $29,014,938 | 3.10% | 25,076 | -36.13% |
| Neurocrine Biosciences Inc | $28,983,018 | 3.10% | 204,336 | -4.25% |
| Indivior Pharmaceuticals Inc | $26,595,824 | 2.84% | 741,864 | +84.91% |
| State STR SPDR S&P 500 ETF T | $24,725,227 | 2.64% | 32,421 | New |
| Bridgebio Pharma Inc | $24,054,506 | 2.57% | 365,570 | +44.29% |
| Thermo Fisher Scientific Inc | $21,591,474 | 2.31% | 31,985 | +12.24% |
| Revolution Medicines Inc | $20,958,893 | 2.24% | 102,109 | -28.71% |
| Jazz Pharmaceuticals PLC | $20,589,305 | 2.20% | 88,931 | -44.68% |
| Humana Inc | $19,489,832 | 2.08% | 51,078 | -45.88% |
| Waters Corp | $19,296,251 | 2.06% | 43,916 | -26.59% |
| Unitedhealth Group Inc | $18,231,395 | 1.95% | 49,666 | -43.74% |
| Abbott Laboratories | $17,436,972 | 1.86% | 176,434 | +114.56% |
| Cytokinetics Inc | $17,058,958 | 1.82% | 258,822 | +35.02% |
| Amneal Pharmaceuticals Inc | $16,573,025 | 1.77% | 822,891 | +71.18% |
| Oscar Health Inc | $15,414,973 | 1.65% | 499,837 | -3.70% |
| Conmed Corp | $14,989,893 | 1.60% | 324,246 | New |
| Madrigal Pharmaceuticals Inc | $14,552,349 | 1.55% | 28,876 | -1.49% |
| Teleflex Incorporated | $14,513,643 | 1.55% | 116,072 | +45.62% |
| Teva Pharmaceutical Inds LTD | $14,067,940 | 1.50% | 355,251 | New |
| Zimmer Biomet Holdings Inc | $13,806,403 | 1.47% | 155,425 | New |
| Glaukos Corp | $13,188,069 | 1.41% | 80,322 | New |
| Edwards Lifesciences Corp | $13,105,275 | 1.40% | 151,822 | -39.38% |
| Definium Therapeutics Inc | $12,753,944 | 1.36% | 335,101 | +34.57% |
| Veeva SYS Inc | $11,326,371 | 1.21% | 39,679 | New |
| Genmab A/s | $11,190,498 | 1.20% | 313,679 | New |
| Exelixis Inc | $11,027,165 | 1.18% | 188,789 | New |
| Irhythm Holdings Inc | $10,978,760 | 1.17% | 96,593 | +48.16% |
| Praxis Precision Medicines I | $10,625,235 | 1.13% | 36,484 | -5.42% |
| Centene Corp Del | $10,532,757 | 1.12% | 169,555 | -31.87% |
| Kodiak Sciences Inc | $10,385,056 | 1.11% | 109,547 | +13.34% |
| Takeda Pharmaceutical Co LTD | $10,315,567 | 1.10% | 567,101 | +27.68% |
| Eupraxia Pharmaceuticals Inc | $10,264,081 | 1.10% | 1,127,921 | -6.83% |
| Danaher Corp Del | $10,116,638 | 1.08% | 45,663 | New |
| Arrowhead Pharmaceuticals In | $9,819,594 | 1.05% | 150,032 | +13.95% |
| Integra Lifesciences Hldgs C | $9,425,811 | 1.01% | 578,981 | +66.02% |
| Belite Bio Inc | $9,353,346 | 1.00% | 55,078 | +58.26% |
| Icon Pub LTD Co | $8,542,677 | 0.91% | 50,254 | -63.18% |
| Ionis Pharmaceuticals Inc | $8,523,908 | 0.91% | 190,905 | New |
| Amylyx Pharmaceuticals Inc | $8,218,829 | 0.88% | 282,434 | +96.54% |
| Elanco Animal Health Inc | $7,723,341 | 0.82% | 344,946 | +99.98% |
| Bio Rad Labs Inc | $7,661,092 | 0.82% | 20,283 | +44.93% |
| Celldex Therapeutics Inc New | $7,642,764 | 0.82% | 235,815 | -31.20% |
| Guardant Health Inc | $7,564,426 | 0.81% | 42,411 | +15.56% |
| Brightspring Health Svcs Inc | $7,241,470 | 0.77% | 127,603 | -10.08% |
| Charles Riv Labs Intl Inc | $7,182,608 | 0.77% | 24,347 | +29.87% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 22 new positions, 39 sold out, 27 increased, 28 reduced and 2 unchanged.
Number of positions (a count, not dollars)
- New positions22
- Increased27
- Unchanged2
- Reduced28
- Sold out39
New positions
| Stock | Value | Shares |
|---|---|---|
| State STR SPDR S&P 500 ETF T | $24,725,227 | 32,421 |
| Conmed Corp | $14,989,893 | 324,246 |
| Teva Pharmaceutical Inds LTD | $14,067,940 | 355,251 |
| Zimmer Biomet Holdings Inc | $13,806,403 | 155,425 |
| Glaukos Corp | $13,188,069 | 80,322 |
| Veeva SYS Inc | $11,326,371 | 39,679 |
| Genmab A/s | $11,190,498 | 313,679 |
| Exelixis Inc | $11,027,165 | 188,789 |
| Danaher Corp Del | $10,116,638 | 45,663 |
| Ionis Pharmaceuticals Inc | $8,523,908 | 190,905 |
| Doximity Inc | $6,409,459 | 226,163 |
| Ge Healthcare Technologies I | $5,463,232 | 83,574 |
| Minimed Group Inc | $3,984,789 | 204,663 |
| Dexcom Inc | $3,977,279 | 46,092 |
| Freenome Inc | $3,650,693 | 231,790 |
| Damora Therapeutics Inc Com SHS | $3,072,023 | 144,362 |
| Twist Bioscience Corp | $2,903,624 | 15,026 |
| Iqvia Hldgs Inc | $2,879,384 | 10,710 |
| Invesco QQQ TR | $2,746,766 | 3,713 |
| 10X Genomics Inc | $1,841,175 | 20,376 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Penumbra Inc | $19,014,781 | 60,221 |
| Stryker Corporation | $17,831,593 | 56,637 |
| Mettler Toledo International | $17,047,093 | 13,344 |
| Merck & Co Inc | $16,334,663 | 127,118 |
| Lantheus Hldgs Inc | $16,241,949 | 146,403 |
| Cooper Cos Inc | $15,840,022 | 220,890 |
| Acadia Healthcare Company In | $15,501,301 | 524,934 |
| Oruka Therapeutics Inc | $15,115,375 | 158,825 |
| CVS Health Corp | $14,219,927 | 137,457 |
| Merit Med SYS Inc | $13,662,615 | 197,038 |
| Novo-nordisk A S | $12,704,867 | 265,016 |
| Integer Hldgs Corp | $11,837,218 | 126,669 |
| Gilead Sciences Inc | $11,479,000 | 90,858 |
| Schein Henry Inc | $11,227,009 | 134,423 |
| Tango Therapeutics Inc | $10,192,229 | 326,047 |
| Roivant Sciences LTD | $9,484,803 | 268,008 |
| CG Oncology Inc | $9,114,720 | 128,286 |
| Arcutis Biotherapeutics Inc | $6,347,049 | 242,069 |
| Illumina Inc | $6,161,083 | 35,040 |
| Meiragtx Hldgs PLC | $6,150,914 | 455,286 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Indivior Pharmaceuticals Inc | +340,656 | +84.91% | $26,595,824 | 741,864 |
| United Therapeutics Corp Del | +19,252 | +38.51% | $37,522,089 | 69,243 |
| Abbott Laboratories | +94,204 | +114.56% | $17,436,972 | 176,434 |
| Bridgebio Pharma Inc | +112,212 | +44.29% | $24,054,506 | 365,570 |
| Amneal Pharmaceuticals Inc | +342,176 | +71.18% | $16,573,025 | 822,891 |
| Teleflex Incorporated | +36,364 | +45.62% | $14,513,643 | 116,072 |
| Cytokinetics Inc | +67,136 | +35.02% | $17,058,958 | 258,822 |
| Omnicell Com | +119,403 | +243.48% | $5,735,484 | 168,443 |
| Amylyx Pharmaceuticals Inc | +138,734 | +96.54% | $8,218,829 | 282,434 |
| Elanco Animal Health Inc | +172,457 | +99.98% | $7,723,341 | 344,946 |
| Integra Lifesciences Hldgs C | +230,235 | +66.02% | $9,425,811 | 578,981 |
| Irhythm Holdings Inc | +31,397 | +48.16% | $10,978,760 | 96,593 |
| Belite Bio Inc | +20,275 | +58.26% | $9,353,346 | 55,078 |
| Definium Therapeutics Inc | +86,081 | +34.57% | $12,753,944 | 335,101 |
| Bio Rad Labs Inc | +6,288 | +44.93% | $7,661,092 | 20,283 |
| Thermo Fisher Scientific Inc | +3,489 | +12.24% | $21,591,474 | 31,985 |
| Takeda Pharmaceutical Co LTD | +122,928 | +27.68% | $10,315,567 | 567,101 |
| Omada Health Inc | +95,854 | +83.76% | $4,376,260 | 210,296 |
| Charles Riv Labs Intl Inc | +5,600 | +29.87% | $7,182,608 | 24,347 |
| Kodiak Sciences Inc | +12,890 | +13.34% | $10,385,056 | 109,547 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | -71,837 | -44.68% | $20,589,305 | 88,931 |
| Humana Inc | -43,297 | -45.88% | $19,489,832 | 51,078 |
| Eli Lilly & Co | -14,182 | -36.13% | $29,014,938 | 25,076 |
| Icon Pub LTD Co | -86,228 | -63.18% | $8,542,677 | 50,254 |
| Unitedhealth Group Inc | -38,610 | -43.74% | $18,231,395 | 49,666 |
| Edwards Lifesciences Corp | -98,631 | -39.38% | $13,105,275 | 151,822 |
| Revolution Medicines Inc | -41,113 | -28.71% | $20,958,893 | 102,109 |
| Waters Corp | -15,909 | -26.59% | $19,296,251 | 43,916 |
| Dianthus Therapeutics Inc | -59,923 | -49.43% | $5,397,377 | 61,299 |
| Centene Corp Del | -79,312 | -31.87% | $10,532,757 | 169,555 |
| Rhythm Pharmaceuticals Inc | -45,563 | -44.87% | $5,330,802 | 55,987 |
| Celldex Therapeutics Inc New | -106,936 | -31.20% | $7,642,764 | 235,815 |
| Vera Therapeutics Inc | -80,316 | -35.81% | $4,648,888 | 143,973 |
| Hinge Health Inc | -24,225 | -29.24% | $5,701,667 | 58,635 |
| Viking Therapeutics Inc | -66,958 | -26.22% | $6,140,927 | 188,372 |
| Abivax SA | -19,358 | -44.74% | $2,367,172 | 23,906 |
| West Pharmaceutical Svsc Inc | -4,424 | -21.34% | $6,046,725 | 16,309 |
| Cullinan Therapeutics Inc | -87,727 | -45.59% | $1,607,375 | 104,715 |
| Neurocrine Biosciences Inc | -9,071 | -4.25% | $28,983,018 | 204,336 |
| Oculis Holding AG | -108,747 | -24.94% | $3,056,935 | 327,295 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Outset Medical, Inc. | 13G amendment | 2.9% | 530,796 | Feb 17, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 17, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private investment funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (6)
As reported in the adviser's Form ADV filed Jun 24, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures